The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC).
J. W. Cook
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
E. Paxinos
No relevant relationships to disclose
L. J. Goodman
No relevant relationships to disclose
S. M. Ali
No relevant relationships to disclose
K. Leitzel
Research Funding - Monogram Biosciences
W. Koestler
Research Funding - Monogram Biosciences
A. Rivera
Employment or Leadership Position - Monogram Biosciences
J. M. Weidler
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
W. Huang
Employment or Leadership Position - Monogram Biosciences
J. Sperinde
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
S. J. Williams
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
M. Bates
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
A. Lipton
Consultant or Advisory Role - Monogram Biosciences
Research Funding - Monogram Biosciences